Thomas Reuters gave a $1.72 EPS consensus estimate for Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s current quarter. However, the company beat this estimate by $0.04 and attained an EPS of $1.76. The consensus estimate of the revenue for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was $1.04 billion; meanwhile, the actual revenue that the company generated over the quarter was worth $1.85 billion. During the same quarter last year, the company earned $1.30 for each share. On year-over-year basis, the company’s revenue over one quarter increased by 76.6%. Analysts have predicted a posting of $8.73 EPS by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in this year. In its last trading session, the company traded in the range $120.56 – $122.79. However, it ended the day at $122.17, decreasing by -0.91%. The company’s ROI is -0.10% and the ROA is -3.30%. The company has shown a monthly performance of -4.15%.

Thomas Reuters also gave an estimate for Alkermes Plc (NASDAQ:ALKS). Alkermes Plc (NASDAQ:ALKS) achieved $0.11 EPS, while the estimate by the Reuters was $0.10, thus, beating the estimate by $0.01. For the quarter, the company generated a $130.21 million revenue, which was lower than the consensus estimate of the quarter earnings of $135.79 million. In the previous year, over the same quarter, the company had posted an EPS of $0.40. This year Alkermes Plc (NASDAQ:ALKS)’s revenue was 20.3% lower as compared to the revenue generated last year. According to a prediction by the analysts, the company will post an EPS worth $0.49 in the current year. In the last trading session, Alkermes Plc (NASDAQ:ALKS) traded in the range $47.34 – $49.21, and ended at $47.94. The weekly performance the company displayed was -4.75% and the quarterly performance was 16.64%. The company is standing -11.63% below its highest value over 52 weeks.

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) posted its results of operations over three months on July 7^th. The six months ended on May 31, 2014. The revenue generated in the three months, that is related to the commercialization and license agreement between IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) and with Par Pharmaceutical, Inc. values up till $1.5 million. These earning were made by 31^st May, 2014. Meanwhile, in the previous year by the same date, the company had generated $Nil revenue. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)’s earnings over the three months that ended in May are because of the commercial sales of their extended-release capsule Focalin XR®. The capsule comes in two strengths, 15mg and 30mg, and is the first product launched by the company.  The company’s market cap is recorded 78.80M with an insider ownership of 39.16%. In the last day-trade, the company began at $3.60 and ended at $3.38.

Flamel Technologies S.A. (ADR) (NASDAQ:FLML) received Prescription Drug User Fee Act from the FDA on June 16^th, 2014. This was for the company’s NDA for one of its Marketed Drugs that wasn’t approved. The company opened its trade on Tuesday at $14.34 and closed it at $13.21. The EPS growth for the company this year is 99.40% whereas the next year’s estimate is 12600.00%. Analysts have set a target of $21.40 for the company.

Get Free Updates and Stock Alerts!

*We only send one email per week